OTCMKTS:ENZN

Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis

$0.08
+0.01 (+14.71%)
(As of 04/23/2024 ET)
Today's Range
$0.08
$0.08
50-Day Range
$0.06
$0.09
52-Week Range
$0.06
$0.23
Volume
125 shs
Average Volume
6,131 shs
Market Capitalization
N/A
P/E Ratio
7.80
Dividend Yield
N/A
Price Target
N/A
ENZN stock logo

About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN)

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

ENZN Stock Price History

ENZN Stock News Headlines

Enzon Pharmaceuticals Inc ENZN
OKYO Pharma Limited (OK10.F)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Enzon Stock Hits New 52-Week Low (ENZN)
Ibnsina Pharma Co (ISPH)
At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
Enzon Pharmaceuticals, Inc. (ENZN)
See More Headlines
Receive ENZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:ENZN
Previous Symbol
NASDAQ:ENZN
CUSIP
29390410
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$1.37 million
Pretax Margin
3,573.08%

Debt

Sales & Book Value

Annual Sales
$30,000.00

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.33
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Richard L. Feinstein (Age 81)
    CEO, CFO & Company Secretary
    Comp: $209.45k

ENZN Stock Analysis - Frequently Asked Questions

How have ENZN shares performed in 2024?

Enzon Pharmaceuticals' stock was trading at $0.0936 at the beginning of 2024. Since then, ENZN stock has decreased by 16.7% and is now trading at $0.0780.
View the best growth stocks for 2024 here
.

Are investors shorting Enzon Pharmaceuticals?

Enzon Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,800 shares, an increase of 137.5% from the March 15th total of 1,600 shares. Based on an average daily volume of 50,100 shares, the days-to-cover ratio is presently 0.1 days.
View Enzon Pharmaceuticals' Short Interest
.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) announced its quarterly earnings results on Wednesday, March, 20th. The biotechnology company reported $0.01 EPS for the quarter.

What other stocks do shareholders of Enzon Pharmaceuticals own?
How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ENZN) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners